人类白细胞抗原
下调和上调
β-2微球蛋白
MHC I级
抗原处理
主要组织相容性复合体
生物
癌症研究
免疫学
抗原呈递
膀胱癌
免疫系统
癌症
抗原
T细胞
基因
遗传学
作者
José María Romero,Pilar Jiménez,Teresa Cabrera,José Manuel Cózar,Susana Pedrinaci,Miguel Tallada,Federico Garrido,Francisco Ruiz‐Cabello
摘要
Downregulation of MHC class I expression is a widespread phenomenon used by tumor cells to escape antitumor T-cell-mediated immune responses. These alterations may play a role in the clinical course of the disease. The aim of our study was to investigate the molecular mechanism underlying the absence of HLA-class I molecule expression in bladder cancer cells. Microdissected tumor tissues were characterized by real-time quantitative PCR for the expression of HLA-ABC, beta2-microglobulin and the members of the antigen processing machinery (APM) of HLA class I molecules (LMP2, LMP7, TAP1, TAP2 and tapasin). Our results showed that irreversible HLA loss by mutations in the beta2-microglobulin gene was not the cause of low HLA class I expression in bladder cancers. In contrast, we observed a coordinated transcription downregulation of HLA-ABC and beta2-microglobulin and APM genes in microdissected tumor tissue derived from bladder carcinomas. This mechanism may represent a major factor for the downregulation of HLA class I expression and in the subsequent direct recognition of cancer cells by cytolytic T lymphocytes. Because this regulatory mechanism is frequently reversible by IFN-gamma treatment, we conclude that HLA class I expression should be a major consideration for immunotherapeutic purposes in patients with bladder cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI